A Multi-Site Break Through Cancer Trial: Targeting Measurable Residual Disease in Patients With Acute Myeloid Leukemia: A Phase 1/2 Study of Tagraxofusp, Azacitidine, and Venetoclax

Clinical trial NCT07148180 · RECRUITING

Trial details

NCT number

NCT07148180

Sponsor

Jacqueline Garcia, MD

Status

RECRUITING

Phase

Phase 1, Phase 2

Study type

INTERVENTIONAL

Start date

2026-02-02

Primary completion

2028-12-31

Enrollment

31

View on ClinicalTrials.gov